Metabolic reprogramming through precise nutrient modulation
Our groundbreaking research shows that by precisely modulating nutrients through diet, we can reprogram metabolism to significantly slow cancer growth and improve the efficacy of standard treatments.Read our research
Cancer-specific nutrient modulation slows tumor growth and increases survival time
Our preclinical research has shown that a serine and glycine restricted diet can significantly improve survival, doubling the 12-month survival rate in one model from 25% to 50%.
Data replicated in numerous other in vivo cancer models including mouse xenograft and allograft tumor models.
Apc min/+ and Eμ-Myc genetically engineered mouse models of cancer
Diet change implemented after tumour initiation at 60-80 days of age (i.e. not from birth)
Intervention is diet only (i.e. without any additional therapeutic agent)
Maddocks et. al. (2017), Nature, 544, 372-376
Faeth dietary intervention makes a targeted therapy more than 500% more effective
Faeth is designed to help create a foundation for many other treatments. In preclinical models, when paired with Faeth, other treatments are as much as 500% more effective.
Pancreatic Cancer In Vivo Model
Syngeneic allograft tumours with mutant Kras & mutant p53
Hopkins et. al. (2018), Nature, 560, 499-503
Validated in over 10 in vivo cancer models with multiple PI3K inhibitors.
Faeth makes standard treatments more effective and optimizes nutrition
When precise control of nutrition levels is combined with existing treatments, our preclinical research has shown we can stop cancer in its tracks.
Pancreatic cancer and normal pancreas tissue organoids derived from multiple human subjects and grown in vitro
NEAAR = Non-essential amino acid restriction (removal of selected non-essential amino acids from growth medium)
Gem-Pac = Gemcitabine and paclitaxel
Every cancer, every patient
We are on a mission to develop treatments for every cancer, every patient. MetabOS is our discovery platform that combines machine learning and the metabolic genome to uncover new metabolic treatments for cancer.
We are in clinical trials with several therapies and our pipeline is robust
A Phase 1b Study of Serabelisib in Combination with an Insulin Suppressing Diet With or Without Nab-paclitaxel in Subjects With Advanced Solid Tumors With PIK3CA Mutations (SER-ISD1-001)
While targeted therapies for cancer, such as PI3K (phosphoinositide 3-kinase) inhibitors, can increase progression free survival, they also cause systemic metabolic side effects that result in decreased efficacy, poor quality of life, noncompliance, and discontinuation.
In preclinical models of cancer, the anticancer efficacy and side effect profile of PI3K inhibitors has been dramatically improved by controlling systemic metabolism with a precisely formulated diet that controls systemic insulin levels (insulin suppressing diet / ISD). Serabelisib is a selective small molecule inhibitor of PI3Kα (phosphoinositide 3-kinase alpha isoform).
Preclinical studies have shown that combining PI3Kα inhibition with ISD resulted in improved efficacy and improved metabolic control versus PI3Kα inhibitor alone.
This study will evaluate the feasibility of optimizing the safety and tolerability of Serabelisib when combined with a precision nutrition insulin suppressing diet (ISD) with or without Nab-paclitaxel with the goal of reducing side effects and significantly enhancing anticancer activity.
Cohort 1 (Dose Modification): Adult subjects with any advanced solid tumor with PIK3CA mutations with or without PTEN loss.
Cohorts 2, 3, and 4 (Cohort Expansion): Adult subjects with PIK3CA-mutations with or without PTEN loss, and advanced colorectal cancer, advanced endometrial cancer, or advanced ovarian clear cell or ovarian endometrioid carcinoma.
Medical Food for the Dietary Management of Advanced/Metastatic Pancreatic Cancer (NEAAR-001)
This is a single arm study evaluating the tolerability and markers of pancreatic cancer with a specially designed medical food restricted in specific amino acids for the dietary management of subjects with locally advanced and unresectable or metastatic pancreatic adenocarcinoma. Subjects will be receiving two FDA approved first line drug therapies, gemcitabine and nab-paclitaxel, that are routinely prescribed in combination for pancreatic cancer as part of their routine care.